Organon Sets Sights On Future Frontiers In Biosimilars
Jon Martin Discusses Firm’s Priorities In The Biosimilars Arena
Following its recent presentation of results for the third quarter of the 2024 fiscal year, Organon’s US biosimilars lead Jon Martin spoke to Generics Bulletin about the company’s adalimumab plans and strategy with upcoming launches, as well as how these will benefit from the firm’s focus on women’s health.
